A GNA feature by Laudia Sawer   Tema, July 12, GNA  -  On any ordinary morning, Maame Esi, an HIV mentor mother, stands among other mothers at the antenatal clinic ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Borey and Sophia are among the first clients in Cambodia to begin long-acting injectable Cabotegravir (CAB-LA), a PrEP ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Over the past three decades, there have been amazing advances in treating and preventing HIV. Subscribe to our newsletter for ...

Jeremy Gregson was sitting in his Northwest Indiana home two years ago when he got the call that his blood work from earlier ...

Elton John and Jeanine White, the mother of Ryan White, urge Congress not to cut funding for lifesaving HIV and AIDS programs ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.